It is a synthetic glucagon-like peptide-1GLP- 1 analogue, which is used to treat type 2 diabetes and obesity. Smegliptide stimulates insulin secretion and lowers blood sugar level by binding GLP- 1 receptor. Compared with traditional diabetes drugs, smectite can better control blood sugar level and lose weight. Smegliptide is an effective drug to treat diabetes and obesity. It can control blood sugar and weight by weekly injection, and has cardiovascular protection.
Smegliptide can also reduce blood pressure and cholesterol levels, and has a certain preventive effect on cardiovascular diseases. Drugs need to be injected once a week, either with a pen syringe or with an automatic syringe. When using smectite, be sure to follow the doctor's advice and the instructions in the instructions. Common adverse reactions include digestive system problems such as nausea, vomiting and diarrhea, as well as nervous system problems such as headache and dizziness. However, we should pay close attention to adverse reactions and follow the doctor's advice and operating instructions. The English name of smeglutide is Semaglutide.
Efficacy of smegliptide:
1, control blood sugar level
Smegliptide can stimulate insulin secretion and reduce blood sugar level, thus effectively controlling type 2 diabetes. Its mechanism of action is to activate GLP- 1 receptor by binding with human GLP- 1 receptor, and then stimulate insulin secretion.
Step 2 lose weight
Smegliptide can inhibit appetite, slow down the gastric emptying speed, thus reducing food intake and achieving the purpose of losing weight. Its mechanism of action is also to inhibit gastric emptying and slow down food intake by binding to GLP- 1 receptor.
3. Protect the cardiovascular system
Studies have shown that smectite can reduce the incidence of major cardiovascular adverse events, including cardiovascular death, nonfatal myocardial infarction or nonfatal stroke. Its mechanism may be related to the related factors of lowering blood pressure and cholesterol levels and reducing cardiovascular events.